Dupixent (dupilumab) – an IL-4 and IL-13 inhibitor – has dominated the market for biological therapies for atopic dermatitis since it was approved by the FDA in 2017.

Dupixent has received regulatory approvals in more than 60 countries in one or more indications including certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps ...

Dupixent (dupilumab) was the first biologic medicine to get approval for atopic dermatitis in 2017, and since then has grown sales to more than $2 billion last year, with Sanofi suggesting it ...

such as atopic dermatitis and asthma — providing patients with one treatment that might help multiple atopy conditions.” Approval of (Dupixent, Regeneron/Sanofi) was based on data from two ...

Beyond CSU, Dupixent is approved in the US for certain cases of atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic oesophagitis, prurigo nodularis and chronic ...

With the recent developments in the atopic dermatitis (AD ... Since their introduction with Sanofi/Regeneron’s Dupixent, biologics have had a dramatic impact on the AD space, offering targeted ...

such as atopic dermatitis and asthma – providing patients with one treatment that might help multiple atopy conditions. We look forward to bringing Dupixent to the more than 300,000 CSU patients ...

Galderma is now facing off against big, established rivals such as Sanofi and Regeneron’s Dupixent for the U.S. atopic dermatitis market. The company is focusing in particular on the effects of ...

On its way to generating sales of $14 billion in just its seventh full year on the market, Sanofi and Regeneron’s Dupixent has experienced few setbacks. One came in 2023, however, when the FDA ...